News and Announcements
Kela Surpasses First Release Target of Shares Issued
- Published March 23, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kela is pleased to announce that we have surpassed our first release target of shares issued.
Our intention is to limit the total issue of shares to 1000 ordinary shares, where by our intended first issue was 750 shares only. With the balance 250 shares to issue later in the year.
We have now reached 850 shares issued and we will be closing this current offer at the end of the march and the remaining shares we will put up for offer again at a later date being August the 25th at a revalued sale price. Please contact us to register your interest in what we anticipate to be short highly sort after offering.
I would also like to announce that we will be exhibiting at our first trade show to the Salon and Beauty Industry this weekend March 25th and 26th at the ‘’beauty expo at the Melbourne Exhibition centre. We will be taking orders and looking for potential distributors in the Salon channel in the Australian market.
Also, our website will be going live end next week and we will be taking orders directly from the public both in Australia and Internationally.
Both the Website launch and the beauty Expo as well as Facebook and Instagram launch this week are in effect a soft launch for the brand, and its anticipated our Major Brand launch with our New Marketing collateral will be mid-May.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
